This agent not only curtails the growth of CRC organoids but also exhibits potent antitumor effects in patient-derived models, showing particular efficacy against tumors with enhanced Lgr5 and EGFR levels, including those harboring KRAS mutations that evade cetuximab treatment. The gene discussed is KRAS; the disease is colorectal carcinoma.